Want to join the conversation?
$CAG 4Q14 Call - John Gehring, CFO: An extra week overall contributed approx. 7% of 4Q15 net sales & volume for each operating segment & reported diluted EPS from continuing operations of $0.47 vs. loss of $0.95 in the year ago period; sharp increase in reported EPS, was driven by significant non-cash impairment charges recorded in year ago quarter
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.